The Foundation Fighting Blindness has released four years of natural history data from its RUSH2A study, giving researchers open access to valuable insights into USH2A-related retinitis pigmentosa and Usher syndrome. This unprecedented data release is expected to accelerate clinical trial development and advance treatments for inherited retinal diseases.

Discover the story of paratriathlete Owen Cravens, who continues to compete, excel, and inspire despite vision loss from Stargardt disease. His determination and heart celebrate what’s possible for anyone facing retinal conditions.

This Thanksgiving week, we’re honoring the power of community gratitude through real reviews and experiences shared by supporters who have encouraged, uplifted, and inspired our family. These heartfelt messages—from donors, parents, and individuals living with visual challenges—remind us that we’re not walking this journey alone. Their compassion fuels our mission to advance sight-saving science for children like Luke.

✨ New Hope for XLRP Patients
The SKYLINE Phase 2 trial of laruzova, a gene therapy for X-linked retinitis pigmentosa, has shown promising vision improvements at 24 months. With the pivotal VISTA Phase 3 trial now fully enrolled, this breakthrough research moves us one step closer to potential treatment for this rare inherited blindness.